Remon, J. http://orcid.org/0000-0002-9462-875X
Bernabé, R.
Diz, P.
Felip, E.
González-Larriba, J. L.
Lázaro, M.
Mielgo-Rubio, X.
Sánchez, A.
Sullivan, I.
Massutti, B.
Article History
Accepted: 20 January 2022
First Online: 5 February 2022
Declarations
:
: JR reports advisory board membership from MSD, BMS, BOHERING INGLEHEIM, ASTRAZENECA and OSE-IMMUOTHERAPEUTICS. RBC has nothing to disclose. PDT reports advisory board membership and speaker’s fees from BMS, AstraZeneca, Boehringer Ingelheim, ROCHE, MSD and TAKEDA; grant from AstraZeneca and speaker’s fees from Pfizer and Amgen. EF reports consultant fees or advisory position from AMGEN, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Merck Serono, MSD Oncology, Novartis, Pfizer, Roche, Sanofi, Takeda, and Peptomyc. Speaker’s fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Medscape, Merck Sharp & Dohme, Peer Voice, Pfizer, Roche, Takeda and CME Outfitters. Research funding from Fundación Merck Salud and Merck KGaA. Other Relationship from GRIFOLS. JLGL has nothing to disclose. MLQ reports advisory board membership and speaker’s fees from BMS, MSD, Boehringer Ingelheim, AstraZeneca and Roche. XMR has nothing to disclose. ASH reports and speaker’s fees from BMS and Roche; Advisory board membership from Sanofi, Astra Zeneca, Novartis, Janssen, Takeda and Pfizer. IS reports advisory board membership, speaker’s fees and grants from Roche, Novartis Boehringer Ingelheim; speaker’s fees and grants from Bristol-Myers Squibb, Pfizer and Merck Sharp & Dohme; speaker’s fees and grants from AstraZeneca. BM has nothing to disclose.
: This article does not contain any studies with human or animal subjects performed by the any of the authors..
: For this type of study informed consent is not required.